K-V Pharma, Hologic Eye $60M Deal To End Makena Feud

Law360, New York (December 6, 2012, 1:54 PM EST) -- K-V Pharmaceutical Co. reached a major milestone in its Chapter 11 case Wednesday, asking a New York bankruptcy judge to approve a $60 million settlement with Hologic Inc. to end their dispute over rights to the debtor's biggest asset, preterm-birth drug Makena.

K-V asked U.S. Bankruptcy Judge Allan L. Gropper to approve the settlement with Hologic and affiliate Cytyc Prenatal Products Corp. over Makena, the rights, title and interest in which K-V purchased from the Hologic parties under a 2008 asset purchase agreement. K-V filed for...
To view the full article, register now.